Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Expanded Access Program for AM0010 (Pegilodecakin) Subcutaneous Injection

Trial Profile

An Expanded Access Program for AM0010 (Pegilodecakin) Subcutaneous Injection

Suspended
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 05 Jul 2018

At a glance

  • Drugs Ilodecakin (Primary)
  • Indications Breast cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
  • Focus Expanded access; Therapeutic Use
  • Sponsors ARMO Biosciences
  • Most Recent Events

    • 25 Jun 2018 Status changed from recruiting to suspended.
    • 19 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top